Iovance Biotherapeutics Stock Is Crashing. And Here's Why Things Could Get Even Worse This Year.

Iovance Biotherapeutics (NASDAQ: IOVA) is a stock that many investors think has a lot of upside. A year ago, regulators approved its cellular therapy, Amtagvi, to treat unresectable (inoperable) or metastatic melanoma.But although it now has an approved drug in its portfolio, Iovance's stock hasn't exactly taken off. In fact, it's been in free fall this year. And what's worse is that the sell-off may not be over. Here's a look at why investors may be concerned about the stock, and why it may not recover anytime soon.Pharmaceutical companies that are unprofitable and in the early stages of their development are often risky investments. And where there are high-risk stocks, there are often short-sellers betting against their success. In Iovance's case, the percentage of short-sellers with respect to its float -- the number of shares available for public trading -- has been rising a lot in the past year:Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool